SLUP-332 Tablets

SLUP-332 Tablets Oral Delivery Profile

SLUP-332 Tablets represents an advanced oral delivery system, engineered to survive gastrointestinal degradation and provide systemic biological activity without the need for traditional parenteral injection.

Pharmacological Architecture

Parameter	Value
Molecular Formula	C28H38N4O6
Molecular Mass	526.6 g/mol
Assay Purity	>98.0%
Appearance	White round compressed tablets

Figure 1: SLUP-332 Tablets GI Tract Dissolution & Absorption

Oral Mechanism of Action

Detailed cascade of actions from ingestion to systemic effect:

1. Functions as a novel, orally bioavailable small-molecule GLP-1 receptor modulator.
2. Engineered specifically to survive gastric acid degradation within the digestive tract.
3. Binds to GLP-1R on pancreatic beta-cells triggering glucose-dependent insulin secretion.
4. Simultaneously slows gastric emptying producing sustained appetite suppression.
5. Avoids the injection-site reactions and needle requirements inherent to traditional GLP-1 agonists.

Figure 2: Rate of Oral Systemic Bioavailability

Primary Research Results

• Outcome 1: Represents the cutting edge of oral metabolic peptide drug delivery.
• Outcome 2: Provides equivalent satiety signaling to injectable Semaglutide in early dose models.
• Outcome 3: Simplifies patient compliance in chronic metabolic research protocols.

Selective Androgen Receptor Modulator (SARM) Pharmacology

SLUP-332 is a non-steroidal selective androgen receptor modulator (SARM) designed to activate the androgen receptor (AR) in muscle and bone tissue while minimizing activity in prostate and sebaceous gland tissues. This tissue selectivity is achieved through differential recruitment of coactivator proteins: in skeletal muscle, SLUP-332-bound AR recruits transcriptional coactivators (SRC-1, GRIP1) that drive myogenic gene expression, while in prostate tissue, the conformational change induced by SLUP-332 binding is insufficient to recruit the tissue-specific coactivators (such as ARA70) required for prostatic gene activation.

1. SLUP-332 binds the ligand-binding domain of the androgen receptor with nanomolar affinity, displacing endogenous androgens.
2. The AR-SLUP-332 complex translocates to the nucleus and binds androgen response elements (AREs) in target gene promoters.
3. In skeletal muscle, coactivator recruitment drives expression of IGF-1, myostatin inhibitors, and satellite cell proliferation markers.
4. In bone, osteoblast AR activation promotes Wnt/β-catenin signaling and increases osteocalcin and alkaline phosphatase expression.
5. The oral tablet formulation provides sustained plasma levels due to favorable oral bioavailability and moderate hepatic first-pass metabolism.

Oral SARM Research Advantages

• Tablet Format: Unlike injectable peptides, SLUP-332 tablets offer research convenience with consistent dosing, no reconstitution, and room-temperature storage.
• Muscle Wasting Research: SARMs are primarily investigated for conditions involving muscle wasting: cancer cachexia, sarcopenia of aging, glucocorticoid-induced myopathy, and disuse atrophy.
• Bone Density: Preclinical models show SARMs increase cortical bone thickness and trabecular bone mineral density without the virilizing effects of testosterone.
• Lipid Effects: SARMs dose-dependently suppress HDL cholesterol and SHBG, important monitoring parameters in research protocols.
• Regulatory Status: No SARMs are currently FDA-approved. SLUP-332 is supplied as a research compound. All human studies are investigational.